[
    [
        {
            "time": "",
            "original_text": "【国盛医药张金洋团队】周观点：详解2019Q2机构医药持仓，继续推荐2+X主线",
            "features": {
                "keywords": [
                    "国盛医药",
                    "张金洋团队",
                    "2019Q2",
                    "机构医药持仓",
                    "2+X主线"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【国盛医药张金洋团队】周观点：详解2019Q2机构医药持仓，继续推荐2+X主线",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 3,
                "Headline_Structure": 8,
                "Source_Recency": 2
            }
        }
    ]
]